Saurabh Saha, Centessa CEO

Medicx­i's mega-start­up Centes­sa rolls out first da­ta for he­mo­phil­ia drug with plans to charge ahead in­to piv­otal test

When Medicxi ear­li­er this year cob­bled to­geth­er Centes­sa — its Russ­ian nest­ing doll of a biotech start­up with 10 port­fo­lio com­pa­nies fold­ed in­to one — the fo­cus from the start was on the promise of each start­up’s lead drug. The first of those can­di­dates is now rolling out da­ta, and it’s sure to add some weight to Centes­sa’s am­bi­tious mis­sion.

Centes­sa sub­sidiary Apcin­teX turned over a topline win for he­mo­phil­ia A/B can­di­date Ser­pin­PC with the drug nail­ing ear­ly bleed rate check­points with what the biotech called a man­age­able safe­ty pro­file, ac­cord­ing to ear­ly Phase IIa da­ta re­leased Thurs­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.